With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to establish its own salesforce to market Treakisym (and other drugs) in Japan. While the company has not yet made a final decision, we think it is highly likely to move to self-commercialisation in order to improve operating margins after its marketing arrangement with Eisai expires. Therefore, we now model self-commercialisation in our base-case valuation
06 Apr 2018
SymBio Pharmaceuticals - Self-commercialisation gains favour
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SymBio Pharmaceuticals - Self-commercialisation gains favour
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
06 Apr 2018 -
Author:
Dr Dennis Hulme -
Pages:
14
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to establish its own salesforce to market Treakisym (and other drugs) in Japan. While the company has not yet made a final decision, we think it is highly likely to move to self-commercialisation in order to improve operating margins after its marketing arrangement with Eisai expires. Therefore, we now model self-commercialisation in our base-case valuation